All results
35 results for breast cancer
-
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 * early…
- Ages
- 18 Years - 130 Years
- Sexes
- All
-
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cance
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment…
- Ages
- 18 Years - N/A
- Sexes
- All
-
Phase I/II Study of Pharmacokinetics and Safety of Epidiferphane and Taxanes in Breast Cancer Patie
Patients with breast cancer are commonly treated with taxane chemotherapy. Some very common side effects of taxanes, such as anemia and peripheral neuropathy,…
- Ages
- 18 Years - 99 Years
- Sexes
- All
-
TAPUR: Testing FDA Approved Drugs That Target Specific Abnormal Tumor Genes in Pts w/Advanced Cancer
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a…
- Ages
- 12 Years - N/A
- Sexes
- All
-
Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid
This is a First-in-Human Phase IA/IB/II open label dose escalation study of intravenous (IV) administration of ONC-392, a humanized anti-CTLA4 IgG1 monoclonal…
- Ages
- 18 Years - N/A
- Sexes
- All
-
DoD Mastectomy
Breast cancer is the most common type of cancer in women. Removal of the breast, called "mastectomy", is performed either when there is cancer-or an increased…
- Ages
- 18 Years - N/A
- Sexes
- All
-
PVT-2201-301
This is a phase 3, multicenter, randomized, placebo-controlled, double-blind study of treatment with brepocitinib (TYK2/JAK1 inhibitor) in adults with…
- Ages
- 18 Years - 75 Years
- Sexes
- All
-
Camostat Mesilate
The purpose of this study is to determine the safety and efficacy of NI-03. The primary objective of the Single-Dose Phase is to assess the pharmacokinetics…
- Ages
- 18 Years - 85 Years
- Sexes
- All
-
Intravesical BCG vs GEMDOCE in NMIBC (BRIDGE)
The study hypothesis is that BCG naïve non-muscle invasive bladder cancer (NMIBC) patients treated with intravesical Gemcitabine + Docetaxel (GEMDOCE) will…
- Ages
- 18 Years - N/A
- Sexes
- All
-
PNOC020:RNA-Lipid Particle Vaccines for Newly Diagnosed Ped HGG and Adult GBM
The primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in…
- Ages
- 21 Years - N/A
- Sexes
- All